Subscribe to RSS
DOI: 10.1055/s-2007-985885
© Georg Thieme Verlag KG Stuttgart · New York
Augmentation of Clozapine with Valproic Acid for Clozapine-Induced Obsessive-Compulsive Symptoms
Publication History
received 04.04.2007
revised 10.05.2007
accepted 12.07.2007
Publication Date:
17 September 2007 (online)
The comorbidity of obsessive-compulsive symptoms (OCS) and schizophrenia has been documented by epidemiological investigations [2] [9] [12]. OCS is thought to markedly increase the risk of suicides in schizophrenia [11]. Within the multiple pathogenetic factors leading to OCS in schizophrenic patients, treatment with atypical antipsychotics such as clozapine has been discussed for a significant subgroup of these patients [6] [10]. Here, we report the improvement of clozapine-induced OCS after dose reduction to minimal sufficient levels facilitated by augmentation with valproic acid.
References
- 1 Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: Antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006; 11 622-632
- 2 Bottas A, Cooke RG, Richter MA. Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia?. J Psychiatry Neurosci. 2005; 30 187-193
- 3 Citrome L. Schizophrenia and valproate. Psychopharmacol Bull. 2003; 37 ((Suppl 2)) 74-88
- 4 Cora-Locatelli G, Greenberg BD, Martin JD, Murphy DL. Valproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry. 1998; 59 82
- 5 Deltito JA. Valproate pretreatment for the difficult-to-treat patient with OCD. J Clin Psychiatry. 1994; 55 500
- 6 Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Progr Neuro-Psychopharmacol Biol Psychiatry. 2003; 27 333-346
- 7 Moore DP. Neuropsychiatric aspects of Sydenham's chorea: a comprehensive review. J Clin Psychiatry. 1996; 57 407-414
- 8 Pasquini M, Garavini A, Biondi M. Nicotine augmentation for refractory obsessive-compulsive disorder. A case report. Progr Neuro-Psychopharmacol Biol Psychiatry. 2005; 29 157-159
- 9 Poyurovsky M, Koran LM. Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. J Psychiatric Res. 2005; 39 399-408
- 10 Reznik I, Yavin I, Stryjer R, Spivak B, Gonen N, Strous R. et al . Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry. 2004; 37 52-56
- 11 Sevincok L, Akoglu A, Kokcu F. Suicidality in schizophrenic patients with and without obsessive-compulsive disorder. Schizophrenia Res. 2007; 90 198-202
- 12 Sievers M, Sato T, Moller HJ, Bottlender R. Obsessive-compulsive disorder (OCD) with psychotic symptoms and response to treatment with SSRI. Pharmacopsychiatry. 2005; 38 104-105
- 13 Zink M, Dressing H. Augmentation of clozapine with atypical antipsychotic substances. Curr Psychiatry Rev. 2005; 1 165-172
- 14 Zink M, Knopf U, Kuwilsky A. Management of clozapine-induced obsessive compulsive symptoms in a man with schizophrenia. Austr NZ J Psychiatry. 2006; 41 293-294
- 15 Zink M, Knopf U, Mase E, Kuwilsky A, Deuschle M. Duloxetine treatment of major depressive episodes in the course of psychotic diseases. Pharmacopsychiatry. 2006; 39 109-111
Correspondence
M. ZinkMD
Central Institute of Mental Health
Department of Psychiatry and Psychotherapy
University of Heidelberg
P.O. Box 12 21 20
68072 Mannheim
Germany
Phone: +49/621/1703 29 11
Fax: +49/621/1703 12 05
Email: mathias.zink@zi-mannheim.de